Galapagos (NASDAQ:GLPG) Shares Gap Down to $32.95

Galapagos NV (NASDAQ:GLPGGet Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $32.95, but opened at $32.18. Galapagos shares last traded at $32.03, with a volume of 49,678 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on GLPG shares. StockNews.com cut Galapagos from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. Bank of America reissued an “underperform” rating and issued a $31.00 target price (down from $41.00) on shares of Galapagos in a research report on Thursday. Finally, Morgan Stanley initiated coverage on shares of Galapagos in a research report on Thursday, March 7th. They issued an “equal weight” rating and a $38.00 price target for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Galapagos has an average rating of “Hold” and a consensus price target of $34.50.

View Our Latest Stock Analysis on Galapagos

Galapagos Stock Performance

The stock has a market capitalization of $2.12 billion, a PE ratio of -14.06 and a beta of 0.26. The firm has a 50 day moving average of $36.35 and a 200-day moving average of $36.88.

Institutional Trading of Galapagos

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its position in Galapagos by 96.4% during the fourth quarter. BNP Paribas Financial Markets now owns 603 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 296 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Galapagos during the 1st quarter valued at $25,000. US Bancorp DE grew its holdings in shares of Galapagos by 157.4% during the 4th quarter. US Bancorp DE now owns 821 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 502 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Galapagos in the fourth quarter worth $44,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Galapagos by 147.9% during the third quarter. Tower Research Capital LLC TRC now owns 1,133 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 676 shares in the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

About Galapagos

(Get Free Report)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.

Featured Stories

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.